1
|
Li J, Zhang X, Wang R, Cao K, Wan L, Ren X, Ding J, Li W. Impact of National Centralized Drug Procurement policy on chemical pharmaceutical enterprises' R&D investment: a difference-in-differences analysis in China. Front Public Health 2024; 12:1402581. [PMID: 39011324 PMCID: PMC11247172 DOI: 10.3389/fpubh.2024.1402581] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2024] [Accepted: 06/12/2024] [Indexed: 07/17/2024] Open
Abstract
Objective This study aimed to evaluate the impact of the National Centralized Drug Procurement (NCDP) policy on chemical pharmaceutical enterprises' R&D investment and provide references for improving NCDP policy design and encouraging innovation in the pharmaceutical industry. Methods Using the panel data of 102 Shanghai and Shenzhen A-share listed enterprises from 2016 to 2022 under the chemical pharmaceutical classification of Shenwan in Wind database as the research sample, this study developed difference-in-differences (DID) models on bid-winning and bid-non-winning enterprises, respectively, to evaluate the impact of NCDP policy on their R&D investment. In addition, this study tested the heterogeneity of bid-winning enterprises based on the bid success rate, the decline of drug price, and enterprise size. Results The NCDP policy could encourage chemical pharmaceutical companies to increase R&D investment, but the low bid success rate and excessive drug price reduction would reduce their R&D enthusiasm, especially for small- and medium-sized enterprises. Discussion It is suggested that the NCDP policy should be further improved: first, revise the bidding rule of the NCDP policy and increase the bid success rate so that more enterprises can win bids, and second, to solve the problem of excessive drug price reduction, evaluate the rationality of bid-winning prices, and introduce a two-way selection mechanism between medical institutions and supply enterprises. Integrate pharmacoeconomic evaluation into the NCDP rules to form a benign competition among enterprises. Third, attention should be paid to supporting policies for small- and medium-sized enterprises. By increasing procurement volume, shortening payment time limits, and increasing the proportion of advance payments, enterprises' cash flow shortages can be alleviated, thus achieving fairness and inclusiveness in the implementation of the NCDP policy.
Collapse
Affiliation(s)
- Jiaming Li
- School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China
| | - Xinyue Zhang
- The Second Affiliated Hospital of Zhejiang Chinese Medical University, Xinhua Hospital of Zhejiang Province, Hangzhou, China
| | - Rui Wang
- School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China
| | - Keyao Cao
- School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China
| | - Luhui Wan
- School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China
| | - Xu Ren
- School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China
| | - Jinxi Ding
- School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China
- Pharmaceutical Market Access Policy Research Center, China Pharmaceutical University, Nanjing, China
| | - Wei Li
- School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China
- Pharmaceutical Market Access Policy Research Center, China Pharmaceutical University, Nanjing, China
| |
Collapse
|
2
|
Lee M, Kim SE, Jeong JH, Park YH, Han HW. Development of service standards and manpower calculation criteria for hospital clinical pharmacies in South Korea: a survey-based study. BMC Health Serv Res 2024; 24:118. [PMID: 38254141 PMCID: PMC10802065 DOI: 10.1186/s12913-023-10530-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2023] [Accepted: 12/26/2023] [Indexed: 01/24/2024] Open
Abstract
BACKGROUND After the revision of the Korean Pharmaceutical Affairs Act, the certification of specialized pharmacists is scheduled to be legally recognized in 2023. Considering that the specialized pharmacist certification was developed based on the working model of hospital clinical pharmacists, it is necessary to establish standards for clinical pharmacists in hospitals and to calculate appropriate manpower. Through this study, we aim to establish practical standards for clinical pharmacists and propose a method for calculating staffing levels based on an investigation of actual workloads. METHODS This survey-based study consisted of two phases. In the first phase, a literature review was conducted to establish standards for clinical pharmacy services, and tasks in relevant literature were classified to identify clinical pharmacy service tasks that are applicable to the practice of Korean hospitals. Additionally, a preliminary survey was conducted to investigate the essential tasks. In the second phase of the investigation, a multicenter survey was conducted targeting pharmacists in facilities with more than 1,000 beds to explore their perceptions and actual workloads related to tasks. RESULTS According to the standards for clinical pharmacists in Korea, clinical pharmacy services consist of a total of 23 tasks, of which 16 have been identified as essential tasks. Essential tasks accounted for 93% of the total tasks in clinical pharmacy services. The average full-time equivalent (FTE) through workload calculation was 2.5 ± 1.9 for each field, while the FTE allocated to actual practice was 2.1 ± 1.6. The distribution of each type of clinical pharmacy service was as follows: 77% for medication therapy management, 13% for medication education, 8% for multidisciplinary team activities, and 3% for medication use evaluation. CONCLUSION This study identified essential tasks common to clinical pharmacy services across different healthcare institutions. However, the FTE of clinical pharmacists in actual practice was insufficient compared to the required amount. In order to establish and expand clinical pharmacy services in a hospital, it is necessary to ensure an adequate workforce for essential tasks.
Collapse
Affiliation(s)
- Mirinae Lee
- Department of Pharmacy, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, 05535, Seoul, South Korea
| | - Seung-Eun Kim
- Department of Pharmacy, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, 05535, Seoul, South Korea
| | - Jee-Hye Jeong
- Department of Pharmacy, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, 05535, Seoul, South Korea
| | - Yoon-Hee Park
- Department of Pharmacy, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, 05535, Seoul, South Korea
| | - Hye-Won Han
- Department of Pharmacy, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, 05535, Seoul, South Korea.
| |
Collapse
|
3
|
Vigneshwaran E, AlShahrani SM, Alanzi AR, Mohammad AAS, Sadiq MMJ, Khan NA, Alavudeen SS. Comparing knowledge, attitudes, and practices in cardiovascular disease prevention and health promotion between community and hospital pharmacists in Saudi Arabia: A cross-sectional study. Saudi Pharm J 2024; 32:101890. [PMID: 38192383 PMCID: PMC10772382 DOI: 10.1016/j.jsps.2023.101890] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2023] [Accepted: 11/30/2023] [Indexed: 01/10/2024] Open
Abstract
Purpose Saudi Arabia is one of the leading nations in the world in terms of the high frequency of chronic diseases and their associated risk factors. Knowledge and awareness are crucial for pharmacists to play an active role in the prevention of cardiovascular diseases (CVD). The current study assessed the pharmacists' knowledge, attitude, and practice to determine the potential differences with respect to their respective practice settings toward CVD prevention and related health promotions. Methods It is a cross-sectional study targeted the registered pharmacists in the Kingdom of Saudi Arabia. An online questionnaire was prepared, and the link was circulated through various social media platforms. Descriptive statistics, multivariate linear regression analysis and chi square test were used to analyze the data accordingly. Results A total of 324 pharmacists were included in the study. Among these, 157 (48.4 %) were community pharmacists, and the remaining were hospital pharmacists (51.6 %). No significant differences in knowledge scores were observed between community and hospital pharmacists. The mean attitude score among community and hospital pharmacists was found to be 26.40 ± 5.125 and 25.09 ± 5.393 respectively, which was statistically significant (p = 0.026). Similarly, the total practice scores across the settings were statistically significant (p = 0.02). Gender plays a significant role in terms of knowledge scores among both community and hospital pharmacists (p = 0.016 & 0.029). Gender, professional practice experience, and number of prescriptions handled and prescriptions with CVD medications showed significant differences in the distribution of positive attitudes and good practice frequency between community and hospital pharmacists. Conclusion It is evident that there is a deficiency in knowledge among hospital pharmacists compared to community pharmacists. Which indicates that there is a need for a rigorous continuous pharmacy education covering the fundamental aspects of CVD primary prevention and health promotion among pharmacists, given more focus on hospital pharmacists.
Collapse
Affiliation(s)
- Easwaran Vigneshwaran
- Department of Clinical Pharmacy, College of Pharmacy, King Khalid University, Abha, Saudi Arabia
| | - Sultan M. AlShahrani
- Department of Clinical Pharmacy, College of Pharmacy, King Khalid University, Abha, Saudi Arabia
| | - Abdullah R. Alanzi
- Department of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia
| | | | | | - Noohu Abdulla Khan
- Department of Clinical Pharmacy, College of Pharmacy, King Khalid University, Abha, Saudi Arabia
| | | |
Collapse
|
4
|
Olivares-Tirado P, Zanga R. Waste in health care spending: A scoping review. INTERNATIONAL JOURNAL OF HEALTHCARE MANAGEMENT 2023. [DOI: 10.1080/20479700.2023.2185580] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/17/2023]
Affiliation(s)
- Pedro Olivares-Tirado
- Research and Development Department of the Superintendency of Health of Chile, Santiago, Chile
- Adjunct researcher at Health Service Development Research Center, University of Tsukuba, Tsukuba, Japan
| | - Rosendo Zanga
- Research and Development Department of the Superintendency of Health of Chile, Santiago, Chile
- School of Public Health, Faculty of Medicine, University of Chile, Santiago, Chile
| |
Collapse
|
5
|
Chen L, Yang Y, Luo M, Hu B, Yin S, Mao Z. The Impacts of National Centralized Drug Procurement Policy on Drug Utilization and Drug Expenditures: The Case of Shenzhen, China. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH 2020; 17:ijerph17249415. [PMID: 33334027 PMCID: PMC7765443 DOI: 10.3390/ijerph17249415] [Citation(s) in RCA: 46] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/09/2020] [Revised: 12/08/2020] [Accepted: 12/10/2020] [Indexed: 02/08/2023]
Abstract
In 2019, the Chinese government implemented the first round of the National Centralized Drug Procurement (NCDP) pilot (so-called “4 + 7” policy) in mainland China, in which 25 drugs were included. We conducted this study to examine the impacts of NCDP policy on drug utilization and expenditures, and to clarify the main factors contributing to drug expenditure changes. This study used drug purchasing order data from the Centralized Drug Procurement Survey in Shenzhen 2019. Drugs related to the “4 + 7” policy were selected as study samples, including 23 “4 + 7” policy-related varieties and 15 basic alternative drugs. Driving factors for drug expenditures changes were analyzed using A.M. index system analysis (Addis A. & Magrini N.’ method). After the implementation of the NCDP policy, the volume of “4 + 7” policy-related varieties increased by 73.8%, among which winning products jumped by 1638.2% and non-winning products dropped by 70.8%; the expenditures of “4 + 7” policy-related varieties decreased by 36.9%. Structure effects (0.47) and price effects (0.78) negatively contributed to the increase in drug expenditures of “4 + 7” policy-related varieties, while volume effects (1.73) had positive influence. NCDP policy successfully decreased drug expenditures of “4 + 7” policy-related varieties with structure effects playing a leading role. However, total drug expenditures were not effectively controlled due to the increasing use of alternative drugs.
Collapse
Affiliation(s)
- Lei Chen
- School of Health Sciences, Wuhan University, 115# Donghu Road, Wuhan 430071, China; (L.C.); (Y.Y.); (M.L.); (B.H.); (S.Y.)
- Global Health Institute, Wuhan University, 115# Donghu Road, Wuhan 430071, China
| | - Ying Yang
- School of Health Sciences, Wuhan University, 115# Donghu Road, Wuhan 430071, China; (L.C.); (Y.Y.); (M.L.); (B.H.); (S.Y.)
- Global Health Institute, Wuhan University, 115# Donghu Road, Wuhan 430071, China
| | - Mi Luo
- School of Health Sciences, Wuhan University, 115# Donghu Road, Wuhan 430071, China; (L.C.); (Y.Y.); (M.L.); (B.H.); (S.Y.)
| | - Borui Hu
- School of Health Sciences, Wuhan University, 115# Donghu Road, Wuhan 430071, China; (L.C.); (Y.Y.); (M.L.); (B.H.); (S.Y.)
| | - Shicheng Yin
- School of Health Sciences, Wuhan University, 115# Donghu Road, Wuhan 430071, China; (L.C.); (Y.Y.); (M.L.); (B.H.); (S.Y.)
| | - Zongfu Mao
- School of Health Sciences, Wuhan University, 115# Donghu Road, Wuhan 430071, China; (L.C.); (Y.Y.); (M.L.); (B.H.); (S.Y.)
- Global Health Institute, Wuhan University, 115# Donghu Road, Wuhan 430071, China
- Correspondence: ; Tel.: +86-27-6875-9118
| |
Collapse
|